Featured in the October issue, Mutarelli analyzes how to approach valuations and impairment testing when managing through the impacts of COVID.
As we head into Q4 2020, the new normal in private capital markets has fully set in, generally defined by prudence and caution, albeit a work in progress.
Business Development Company market participants are focused keenly on valuation in the wake of the novel coronavirus and the impact on their underlying portfolio investments.
Private asset valuations snapped back in Q2 as the economy began to reopen, and private capital investors took concrete steps to shore up portfolio companies.
Observations and measures of how COVID-related events through August 31, 2020, have impacted equity market indices, adjustments to EBITDA expectations, and their influence on enterprise values by sector.
Observations and measures of how H1 2020 COVID-related events have impacted equity market indices, adjustments to EBITDA expectations, and their influence on enterprise values by sector.
A Q2 2020 update on credit spreads and required returns.
Considering the virus’ material impact on specific industries, we’ve seen a greater emphasis on secondary industry-specific loan indexes when controlling for credit risk.
The COVID-19 market dislocation could be compared, not only to the Great Recession, but also—inversely—to the “irrational exuberance” of the dot-com era.
As private credit manager valuation leaders scrutinize how to optimize their internal teams, they also are leveraging technology tools and third-party service providers—both domestic and offshore—to meet the demands of scale.